20/20 Biolabs Inc. AIDX

 — 
0.43 0.01 2.38% as of 25 Sep
Market cap
$5.4M
P/E
0.0×
Dec '25 Dec '24
P/E ratio
0.00 0.00
P/S ratio
0.00 0.00
P/FCF ratio
0.00 0.00
P/Operating CF
(59.91) (59.91)
P/B ratio
0.00 0.00
Price to Tangible BV
0.00 0.00
EV/Sales
0.00 0.00
EV/EBITDA
0.00 0.00
EV/Operating CF
(20.70) (20.70)
EV/FCF
(20.70) (20.70)
Quick Ratio
0.50 1.42
Current Ratio
0.60 1.50
Net Debt/EBITDA
0.11 0.32
Debt/Assets
16.77% 0.00%
Debt/Equity
(36.15) 0.00
Asset Turnover
0.53 0.00
Operating CF/Net income
0.51 0.47
Capex/Depreciation
0.00 0.00
Interest Coverage
0.00 0.00
ROE
(537.07%) 0.00%
ROA
(96.84%) 0.00%
ROIC
0.00% 0.00%
Return on Tangible Assets
399.74% (697.63%)
Average Days of Receivables
35.70 28.18
Research and Development Expense of Revenue
28.98% 72.01%
Selling, General and Administrative Expense of Revenue
163.45% 271.62%
Intangible Assets out of Total Assets
0.26 0.35
Share Based Compensation of Revenue
25.24% 124.19%
Graham Net Nets
(0.02) (0.02)
Graham Number
0.00 0.00
Earnings Yield
(158.71%) (158.71%)
Free Cash Flow Yield
(4.82%) (4.82%)
Revenue per Share
0.41 0.37
Operating CF per Share
(0.39) (0.54)
Capex per Share
0.00 0.00
Free Cash Flow per Share
(0.39) (0.54)
Cash per Share
0.21 0.37
Shareholders Equity per Share
0.00 0.31
Interest Debt per Share
0.00 0.00
Book value per Share
0.00 0.31
Free Cash Flow
(1.92) (2.60)
Working Capital
(0.99) 0.68
Net Current Asset Value
(2.69) (0.04)
EV/EBIT
0.00 0.00
Capex to Sales
0.00 0.00
Net Profit Margin
(182.82%) (316.82%)
Price to Operating Income
0.00 0.00
Other line items
Depreciation/Fixed assets
3.41 1.21
Cash ROIC
(116.20%) (82.55%)
Accounts Receivable Turnover
12.20 0.00
Accounts Payable Turnover
2.32 0.00
Inventory Turnover
17.63 0.00
Average Days of Payables
220.05 97.62
Days of Inventory on Hand
29.44 12.38
Average Receivables
0.17 —
Average Payables
0.62 —
Average Inventory
0.08 —
Average Assets
3.86 —
Average Common Equity
0.70 —

Fold the line items

Columns are period end dates